{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:05:27Z","timestamp":1764194727930},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background:<\/jats:title>\n                <jats:p>Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states of the USA. Tick\u2019s bites were suspected of generating cross-reactions between cetuximab and alpha-gal. This study aims was to describe the incidence and associated risk factors of CI-IRs, in the French areas chosen according to their Lyme disease incidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods:<\/jats:title>\n                <jats:p>A retrospective chart review was conducted on patients that received cetuximab infusion from January 2010 to June 2019 in 4 French areas with different Lyme disease incidence rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results:<\/jats:title>\n                <jats:p>Of 1392 patients, 117 (8.4%) experienced a CI-IR, including 68 severe (grade 3 or 4) reactions (4.9%). This CI-IR incidence was significantly higher in the Lyme disease high-risk area than in the other areas (13.2% versus 7.1%, 8.1% and 6.4%; P\u2009=\u20090.016). Sex (P\u2009=\u20090.53), premedication (P\u2009=\u20090.91), primary cancer location (P\u2009=\u20090.46) and chemotherapy regimen type (P\u2009=\u20090.78) had no impact on CI-IR incidence in the overall population. In the head and neck squamous cell carcinoma (HNSCC) patient subgroup, CI-IRs were significantly more frequent in the high-risk area (16.4% versus 6.7%, 7.1% and 7.0%; P\u2009=\u20090.0015).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion:<\/jats:title>\n                <jats:p>This study suggests that patients treated in the French area with the highest incidence of Lyme disease are at a higher risk of CI-IRs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10192-4","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T21:47:36Z","timestamp":1669412856000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?"],"prefix":"10.1186","volume":"22","author":[{"given":"M","family":"Dupont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gower-Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Barbier-Lider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Botsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Burgevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chourbagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"D\u2019Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hentzien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lamuraglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lavau-Denes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Slimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Brugel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"10192_CR1","unstructured":"ImClone Systems Incorporated. U.S. Food and Drug Administration. Erbitux (cetuximab) prescribing information. 2019."},{"key":"10192_CR2","unstructured":"European Medicines Agency. European public assessment report for Erbitux (cetuximab). 2020."},{"issue":"10","key":"10192_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","volume":"51","author":"JM Phelip","year":"2019","unstructured":"Phelip JM, Tougeron D, L\u00e9onard D, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357\u201363.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10192_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567\u201378.","journal-title":"N Engl J Med"},{"issue":"11","key":"10192_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"10192_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"J-P Machiels","year":"2020","unstructured":"Machiels J-P, Ren\u00e9 Leemans C, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462\u201375.","journal-title":"Ann Oncol"},{"issue":"20","key":"10192_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med. 2007;357(20):2040\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"10192_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med. 2004;351(4):337\u201345.","journal-title":"N Engl J Med"},{"issue":"7","key":"10192_CR9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/annonc\/mdp535","volume":"21","author":"KA Foley","year":"2010","unstructured":"Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010;21(7):1455\u201361.","journal-title":"Ann Oncol"},{"issue":"6","key":"10192_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/jjco\/hyu049","volume":"44","author":"K Yamaguchi","year":"2014","unstructured":"Yamaguchi K, Watanabe T, Satoh T, et al. Severe Infusion Reactions to Cetuximab Occur within 1\u00a0h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Patients in Japan. Jpn J Clin Oncol. 2014;44(6):541\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10192_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/157488412799218806","volume":"7","author":"X Song","year":"2012","unstructured":"Song X, Long R, Barber S. B et al. Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer. Curr Clin Pharmacol. 2012;7(1):56\u201365.","journal-title":"Curr Clin Pharmacol"},{"issue":"11","key":"10192_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, et al. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-\u03b1-1,3-Galactose. N Engl J Med. 2008;358(11):1109\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"10192_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaip.2019.09.017","volume":"8","author":"TAE Platts-Mills","year":"2020","unstructured":"Platts-Mills TAE, Li RC, Keshavarz B, et al. Diagnosis and Management of Patients with the alpha-Gal Syndrome. J Allergy Clin Immunol Pract. 2020;8(1):15\u201323.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10192_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.alit.2019.04.001","volume":"68","author":"Y Chinuki","year":"2019","unstructured":"Chinuki Y, Morita E. Alpha-Gal-containing biologics and anaphylaxis. Allergol Int. 2019;68(3):296\u2013300.","journal-title":"Allergol Int"},{"issue":"7","key":"10192_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/1744666X.2020.1782745","volume":"16","author":"SP Commins","year":"2020","unstructured":"Commins SP. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clinical Immunol. 2020;16(7):667\u201377.","journal-title":"Expert Rev Clinical Immunol"},{"issue":"1","key":"10192_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13071-019-3413-z","volume":"12","author":"J de la Fuente","year":"2019","unstructured":"de la Fuente J, Pacheco I, Villar M, et al. The alpha-Gal syndrome: new insights into the tick-host conflict and cooperation. Parasit Vectors. 2019;12(1):154.","journal-title":"Parasit Vectors"},{"issue":"6","key":"10192_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy. Oncologist. 2008;13(6):725\u201332.","journal-title":"Oncologist"},{"issue":"4","key":"10192_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0300060517713531","volume":"45","author":"K Ikegawa","year":"2017","unstructured":"Ikegawa K, Suzuki S, Nomura H, et al. Retrospective analysis of premedication, glucocorticosteroids, and H 1 -antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. J Int Med Res. 2017;45(4):1378\u201385.","journal-title":"J Int Med Res"},{"issue":"7","key":"10192_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/cncr.24945","volume":"116","author":"S Siena","year":"2010","unstructured":"Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer. 2010;116(7):1827\u201337.","journal-title":"Cancer"},{"issue":"6","key":"10192_CR20","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1177\/1078155218811505","volume":"25","author":"CG Durham","year":"2019","unstructured":"Durham CG, Thotakura D, Sager L, et al. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019;25(6):1396\u2013401.","journal-title":"J Oncol Pharm Pract"},{"issue":"24","key":"10192_CR21","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","volume":"25","author":"BH O\u2019Neil","year":"2007","unstructured":"O\u2019Neil BH, Allen R, Spigel DR, et al. High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History. J Clin Oncol. 2007;25(24):3644\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"10192_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/1078155209360853","volume":"17","author":"NL Hansen","year":"2011","unstructured":"Hansen NL, Chandiramani DV, Morse MA, et al. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract. 2011;17(2):125\u201330.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10192_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1177\/1078155218780514","volume":"25","author":"D Atwal","year":"2019","unstructured":"Atwal D, Safar AM, Govindarajan R, Makhoul I. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. J Oncol Pharm Pract. 2019;25(5):1130\u20134.","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10192_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.oraloncology.2014.06.017","volume":"50","author":"W Touma","year":"2014","unstructured":"Touma W, Koro SS, Ley J, et al. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(9):895\u2013900.","journal-title":"Oral Oncol"},{"issue":"15_suppl","key":"10192_CR25","doi-asserted-by":"publisher","first-page":"20503","DOI":"10.1200\/jco.2008.26.15_suppl.20503","volume":"26","author":"SN Waqar","year":"2008","unstructured":"Waqar SN, Tan BR, Zubal B, et al. Race and albuterol premedication are risk factors for hypersensitivity reactions to cetuximab. J Clin Oncol. 2008;26(15_suppl):20503.","journal-title":"J Clin Oncol"},{"issue":"2","key":"10192_CR26","first-page":"72","volume":"8","author":"TJ George","year":"2010","unstructured":"George TJ, Laplant KD, Walden EO, et al. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010;8(2):72\u20137.","journal-title":"J Support Oncol"},{"issue":"2","key":"10192_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1078155212457965","volume":"19","author":"A Grandvuillemin","year":"2013","unstructured":"Grandvuillemin A, Disson-Dautriche A, Miremont-Salam\u00e9 G, et al. Cetuximab infusion reactions: French pharmacovigilance database analysis. J Oncol Pharm Pract. 2013;19(2):130\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10192_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1078155212462440","volume":"19","author":"S Hopps","year":"2013","unstructured":"Hopps S, Medina P, Pant S, et al. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract. 2013;19(3):222\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10192_CR29","doi-asserted-by":"publisher","first-page":"e000346","DOI":"10.1136\/esmoopen-2018-000346","volume":"3","author":"V Palomar Coloma","year":"2018","unstructured":"Palomar Coloma V, Bravo P, Lezghed N, et al. High incidence of cetuximab-related infusion reactions in head and neck patients. ESMO Open. 2018;3(5):e000346.","journal-title":"ESMO Open"},{"issue":"6","key":"10192_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1078155213510542","volume":"20","author":"K Keating","year":"2014","unstructured":"Keating K, Walko C, Stephenson B, et al. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. J Oncol Pharm Pract. 2014;20(6):409\u201316.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10192_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1177\/1078155215618771","volume":"22","author":"CB Adams","year":"2016","unstructured":"Adams CB, Street DS, Crass M, Bossaer JB. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect? J Oncol Pharm Pract. 2016;22(6):784\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10192_CR32","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1097\/MJT.0000000000000709","volume":"25","author":"AA Baxley","year":"2018","unstructured":"Baxley AA, Doyin-Lipede OA, Razaq MA. Hypersensitivity to Cetuximab After Geographic Relocation. Am J Ther. 2018;25(6):e699\u2013700.","journal-title":"Am J Ther"},{"issue":"15_suppl","key":"10192_CR33","doi-asserted-by":"publisher","first-page":"20747","DOI":"10.1200\/jco.2008.26.15_suppl.20747","volume":"26","author":"R Owera","year":"2008","unstructured":"Owera R, Gill A, Haddadin S, et al. High incidence of hypersensitivity reactions to cetuximab infusions in mid-Missouri: Association with prior history of atopy. J Clin Oncol. 2008;26(15_suppl):20747.","journal-title":"J Clin Oncol"},{"issue":"5","key":"10192_CR34","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2011.02.019","volume":"127","author":"SP Commins","year":"2011","unstructured":"Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-\u03b1-1,3-galactose. J Allergy Clin Immunol. 2011;127(5):1286\u201393.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10192_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11882-009-0079-1","volume":"10","author":"SP Commins","year":"2010","unstructured":"Commins SP, Platts-Mills TAE. Allergenicity of Carbohydrates and Their Role in Anaphylactic Events. Curr Allergy Asthma Rep. 2010;10(1):29\u201333.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10192_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/all.12344","volume":"69","author":"S Michel","year":"2014","unstructured":"Michel S, Scherer K, Heijnen IAFM, Bircher AJ. Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat. Allergy. 2014;69(3):403\u20135.","journal-title":"Allergy"},{"issue":"2","key":"10192_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.iac.2015.01.009","volume":"35","author":"TAE Platts-Mills","year":"2015","unstructured":"Platts-Mills TAE, Schuyler AJ, Tripathi A, Commins SP. Anaphylaxis to the Carbohydrate Side Chain Alpha-gal. Immunol Allergy Clin North Am. 2015;35(2):247\u201360.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10192_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/1346-8138.12140","volume":"40","author":"JH Lee","year":"2013","unstructured":"Lee JH, Kim JH, Kim TH, Kim S-C. Delayed mammalian meat-induced anaphylaxis confirmed by skin test to cetuximab. J Dermatol. 2013;40(7):577\u20138.","journal-title":"J Dermatol"},{"issue":"3","key":"10192_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaci.2014.12.1947","volume":"135","author":"JW Steinke","year":"2015","unstructured":"Steinke JW, Platts-Mills TAE, Commins SP. The alpha-gal story: Lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589\u201396.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10192_CR40","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.ttbdis.2021.101674","volume":"12","author":"I Young","year":"2021","unstructured":"Young I, Prematunge C, Pussegoda K, et al. Tick exposures and alpha-gal syndrome: A systematic review of the evidence. Ticks Tick Borne Dis. 2021;12(3):101674.","journal-title":"Ticks Tick Borne Dis"},{"key":"10192_CR41","doi-asserted-by":"publisher","first-page":"680264","DOI":"10.3389\/fcimb.2021.680264","volume":"11","author":"SR Sharma","year":"2021","unstructured":"Sharma SR, Karim S. Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack. Front Cell Infect Microbiol. 2021;11:680264.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9814","key":"10192_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","volume":"379","author":"G Stanek","year":"2012","unstructured":"Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. The Lancet. 2012;379(9814):461\u201373.","journal-title":"The Lancet"},{"issue":"4","key":"10192_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/all.12128","volume":"68","author":"C Hamsten","year":"2013","unstructured":"Hamsten C, Starkhammar M, Tran TAT, et al. Identification of galactose-\u03b1-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy. Allergy. 2013;68(4):549\u201352.","journal-title":"Allergy"},{"issue":"1","key":"10192_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1081-1206(10)63082-7","volume":"79","author":"E Beaudouin","year":"1997","unstructured":"Beaudouin E, Kanny G, Guerin B, et al. Unusual Manifestations of Hypersensitivity After a Tick Bite: Report of Two Cases. Ann Allergy Asthma Immunol. 1997;79(1):43\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10192_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/00034983.2001.11813619","volume":"95","author":"P Fern\u00e1ndez-Soto","year":"2001","unstructured":"Fern\u00e1ndez-Soto P, D\u00e1vila I, Laffond E, et al. Tick-bite-induced anaphylaxis in Spain. Ann Trop Med Parasitol. 2001;95(1):97\u2013103.","journal-title":"Ann Trop Med Parasitol"},{"issue":"6","key":"10192_CR46","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaci.2013.07.050","volume":"132","author":"C Hamsten","year":"2013","unstructured":"Hamsten C, Tran TAT, Starkhammar M, et al. Red meat allergy in Sweden: Association with tick sensitization and B-negative blood groups. J Allergy Clin Immunol. 2013;132(6):1431\u20134.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10192_CR47","doi-asserted-by":"publisher","first-page":"1800134","DOI":"10.2807\/1560-7917.ES.2019.24.11.1800134","volume":"24","author":"A Septfons","year":"2019","unstructured":"Septfons A, Goronflot T, Jaulhac B, et al. Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016. Euro Surveill. 2019;24(11):1800134.","journal-title":"Euro Surveill"},{"key":"10192_CR48","unstructured":"National Cancer Institute (U.S. Department of Health and Human Services). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017."},{"issue":"16","key":"10192_CR49","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R, et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. J Clin Oncol. 2007;25(16):2171\u20137.","journal-title":"J Clin Oncol"},{"issue":"13","key":"10192_CR50","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2007;25(13):1658\u201364.","journal-title":"J Clin Oncol"},{"key":"10192_CR51","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J. Clin. Oncol. 2007; 25(18_suppl):4000.","DOI":"10.1200\/jco.2007.25.18_suppl.4000"},{"issue":"14","key":"10192_CR52","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2217\/fon.14.153","volume":"10","author":"B Dupont","year":"2014","unstructured":"Dupont B, Mariotte D, Clarisse B, et al. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol. 2014;10(14):2133\u201340.","journal-title":"Future Oncol"},{"issue":"4","key":"10192_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12032-017-0902-9","volume":"34","author":"E Burke","year":"2017","unstructured":"Burke E, Rockey M, Grauer D, et al. Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center. Med Oncol. 2017;34(4):51.","journal-title":"Med Oncol"},{"issue":"3\u20134","key":"10192_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000454808","volume":"171","author":"S Bavbek","year":"2016","unstructured":"Bavbek S, Kendirlinan R, \u00c7er\u00e7i P, et al. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics. Int Arch Allergy Immunol. 2016;171(3\u20134):227\u201333.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10192_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.18176\/jiaci.0031","volume":"26","author":"JM Garc\u00eda-Menaya","year":"2016","unstructured":"Garc\u00eda-Menaya JM, Cordob\u00e9s-Dur\u00e1n C, G\u00f3mez-Ulla J, et al. Successful Desensitization to Cetuximab in a Patient With a Positive Skin Test to Cetuximab and Specific IgE to Alpha-gal. J Investig Allergol Clin Immunol. 2016;26(2):132\u20134.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10192_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/eci.11.75","volume":"8","author":"DI Hong","year":"2012","unstructured":"Hong DI, Bankova L, Cahill KN, et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012;8(1):43\u201354.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10192_CR57","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaci.2008.09.046","volume":"123","author":"MR Jerath","year":"2009","unstructured":"Jerath MR, Kwan M, Kannarkat M, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol. 2009;123(1):260\u20132.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10192_CR58","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.jaip.2017.11.033","volume":"6","author":"E P\u00e9rez-Rodr\u00edguez","year":"2018","unstructured":"P\u00e9rez-Rodr\u00edguez E, Mart\u00ednez-Tadeo JA, P\u00e9rez-Rodr\u00edguez N, et al. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol. J Allergy Clin Immunol Pract. 2018;6(5):1621\u20137.e6.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10192_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00280-009-1009-6","volume":"65","author":"MW Saif","year":"2009","unstructured":"Saif MW, Syrigos KI, Hotchkiss S, et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2009;65(1):107\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10192_CR60","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1177\/1078155218793505","volume":"25","author":"M Solduzian","year":"2019","unstructured":"Solduzian M, Anvari S, Taghvaye Masoumi H, et al. Successful desensitization of a patient with cetuximab hypersensitivity: A case report. J Oncol Pharm Pract. 2019;25(7):1726\u201330.","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10192_CR61","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3816\/CCC.2007.n.019","volume":"6","author":"J Heun","year":"2007","unstructured":"Heun J, Holen K. Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report. Clin Colorectal Cancer. 2007;6(7):529\u201331.","journal-title":"Clin Colorectal Cancer"},{"key":"10192_CR62","unstructured":"Amgen, Incorporated. U.S. Food and Drug Administration. Vectibix (panitumumab) prescribing information. 2017."},{"issue":"18_suppl","key":"10192_CR63","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1200\/jco.2006.24.18_suppl.3548","volume":"24","author":"J Berlin","year":"2006","unstructured":"Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing \u2265 10% epidermal growth factor receptor (EGFr). J Clin Oncol. 2006;24(18_suppl):3548.","journal-title":"J Clin Oncol"},{"issue":"1","key":"10192_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","volume":"18","author":"M Cohenuram","year":"2007","unstructured":"Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18(1):7\u201315.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10192_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A. Randomized Phase III. Trial Results of Panitumumab, a Fully Human Anti\u2014Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2006;6(1):29\u201331.","journal-title":"Clin Colorectal Cancer"},{"key":"10192_CR66","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/jco.2006.24.18_suppl.3547","volume":"24","author":"J Hecht","year":"2006","unstructured":"Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1\u20139%) or negative (< 1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol. 2006;24:3547. (18_suppl).","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10192-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:27:15Z","timestamp":1669415235000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10192"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10192-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A database was created in accordance with the reference methodology MR004 of the National Commission of Liberties and Informatics (n\u00b02206749, 13\/09\/2018). A non-opposition form was sent to each living patient included in the study. As per French regulations, no additional ethical committee review was required.Decree No. 2016\u2009\u2212\u20091537 of November 16, 2016 relating to research involving the human person. This decree is taken for the application of the modified law n\u00b0 2012\u2009\u2212\u2009300 of March 12, 2012 relating to research involving the human person known as \u201cLoi Jard\u00e9\u201d.Non-interventional research (Category 3): This is research that does not involve any risk or constraint, does not modify the care of the participants and in which all the acts are performed and the products used in the usual way. They are also referred to as \u201cobservational research\u201d. For example, they may relate to treatment compliance, monitoring of a drug after it has been marketed, the practices of one healthcare center compared to those of another, etc.Category 3 searches also require receiving:\u2022 an authorization from the Commission Nationale Informatique et Libert\u00e9 (CNIL) or respecting a reference methodology (MR004) concerning the processing of the personal data of the persons involved.\u2022 informing the ANSM of the opinion issued by the Committee for the Protection of Persons, without its authorization being required.\u2022 the information of the people involved in the research and the collection of their non-objection to the use of the data collected.The Jard\u00e9 law considers that it is not a study on human beings but a study on medical records (and therefore that there is no need for an opinion from a committee for the protection of people) The CNIl reference methodology MR004 imposes patient information (non-objection form) with an exemption from information for deceased subjects (if the subject did not express his opposition to the use of its data for research).No administrative permissions were required to access the raw data used in ourstudy.The data used in this study were anonymised before its use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C-GR reports honoraria as a speaker and\/or in an advisory role from Takeda, Gilead, Ferring, and Tillots, unrelated to this work. DB reports honoraria as a speaker and\/or in an advisory role from Amgen, Accord Healthcare, Sanofi, Servier, Roche and Pierre Fabre, unrelated to this work.MB reports honoraria as a speaker and\/or in an advisory role from Astra-Zeneca, Amgen and Bayer, unrelated to this work. VH reports honoraria as a speaker and\/or in an advisory role from Merck KGaA and Amgen, unrelated to this work. AL reports research funding from Roche, and honoraria as a speaker and\/or in an advisory role from Amgen, and receiving lecture fees from Vifor Pharma, Bayer, Merck, Sanofi, and Ipsen, unrelated to this work. FS reports honoraria as a speaker and\/or in an advisory role from Gilead, and Astra-Zeneca, unrelated to this work. OB reports honoraria as a speaker and\/or in an advisory role from Merck KGaA, Roche Genentech, Bayer, MSD, Amgen, Sanofi, Servier, and Pierre Fabre, unrelated to this work. All remaining authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1219"}}